Company / Interest Expense
Jazz Pharmaceuticals Interest Expense History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$32.8M
FY2023
5-year range
$32.8M / $87.6M
FY2019-FY2023
Trend
-62.6%
vs FY2022
Sector context
#16 of 44
Health Care
What the data says
At $33M, Jazz Pharmaceuticals's interest expense ranks #29 of 44 in the Health Care sector. Improved from $63M to $33M over the past 2 years.
Based on SEC 10-K filings.
$33M in FY2023 with a 5-year CAGR of +3.6%.
Improved from $63M to $33M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -16.7%
- 5-Year CAGR
- +3.6%
- 10-Year CAGR
- -
Sector benchmark
#29 of 44 in Health CareTop 64% of 44This company $32.8M Sector average $291.0M
▼
-88.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.6%, indicating consistent growth.
- In FY2023, interest expense decreased 62.6% year-over-year.
- Ranks #16 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $32.8M | -62.6% |
| FY2022 | $87.6M | +40.2% |
| FY2021 | $62.5M | +10.2% |
| FY2020 | $56.7M | +50.0% |
| FY2019 | $37.8M | +37.5% |
| FY2018 | $27.5M | -27.2% |
| FY2017 | $37.8M | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026